ALB and hepatocellular carcinoma: In 2015, Anthony et al. first formed a novel inflammation-based marker—AAPR through integrating ALB and ALP, and demonstrated that the lower AAPR predict inferior overall survival (OS) in patients with hepatocellular carcinoma (HCC) compared with higher AAPR [9].